Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571033 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL3035552 | 0.74 | F10 (0.48) | F10KDM4ENPC1GAAMAPK1 | |
| SCHEMBL2569536 | 0.69 | AR (0.58) | F10SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL14990787 | 0.69 | MAPT (0.72) | ALDH1A1MAPTTP53POLB | |
| SCHEMBL3031171 | 0.66 | F10 (0.48) | F10SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL2568280 | 0.66 | DHFR (0.53) | NPC1ALDH1A1GAARAB9AKMT2A | |
| SCHEMBL3035672 | 0.66 | F10 (0.52) | F10SMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL3025755 | 0.65 | AR (0.60) | F10SMN1; SMN2NPC1ALDH1A1MAPK1 | |
| SCHEMBL8244335 | 0.65 | F10 (0.54) | F10SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL3027914 | 0.65 | F10 (0.61) | F10SMN1; SMN2KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691960-B2 | 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691960-B2 | 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220144796-A1 | 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-1899330-B1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| WO-2007003536-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691960-B2 | 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament | IDO1, IDO2, INMT | F10 4273/4885SMN1; SMN2 1759/4885KDM4E 225/4885 |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | F10 1271/4885SMN1; SMN2 3359/4885KDM4E 3299/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | F10 1439/4885SMN1; SMN2 3286/4885KDM4E 3054/4885 |
| US-20220144796-A1 | 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament | IDO1, IDO2, TPH1 | F10 3905/4885SMN1; SMN2 1939/4885KDM4E 743/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | F10 1439/4885SMN1; SMN2 3286/4885KDM4E 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.